Compare
Matinas BioPharma Holdings, Inc. vs Cannapharmarx, Inc. vs Ensysce Biosciences, Inc. vs CV Sciences, Inc.
| Latest fiscal year | Matinas BioPharma Holdings, Inc. MTNB | Cannapharmarx, Inc. CPMD | Ensysce Biosciences, Inc. ENSC | CV Sciences, Inc. CVSI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.36M | $5.07M | $13.79M |
| Revenue growth (YoY) | n/a | +66.1% | -2.8% | -12.2% |
| Gross margin | n/a | -153.1% | n/a | 49.0% |
| Operating margin | n/a | -245.8% | -202.1% | -3.4% |
| Net margin | n/a | -817.2% | -200.8% | -6.9% |
| Net income | -$10.35M | -$11.13M | -$10.18M | -$958.0K |
| EPS (Diluted) | -$2.00 | -$0.02 | -$3.98 | -$0.01 |
| Operating cash flow | -$7.01M | -$789.1K | -$7.81M | -$407.0K |
| Free cash flow | n/a | -$794.6K | -$7.93M | -$516.0K |
| Cash & equivalents | $4.00M | $1.8K | $4.31M | n/a |
| Total assets | $7.21M | $7.02M | $7.45M | $6.96M |
| Total liabilities | $2.38M | $37.17M | $4.57M | $5.49M |
| Shareholders' equity | $4.83M | -$30.15M | $3.21M | $1.47M |
| Return on year-end equity | -214.2% | n/a | -316.6% | -65.3% |
| Shares outstanding | 6.41M | 662.50M | 4.57M | 184.26M |
Revenue, most recent five fiscal years
| Fiscal year | Matinas BioPharma Holdings, Inc. | Cannapharmarx, Inc. | Ensysce Biosciences, Inc. | CV Sciences, Inc. |
|---|---|---|---|---|
| Latest | $1.10M Ended 2023-12-31 | $1.36M Ended 2025-12-31 | $5.07M Ended 2025-12-31 | $13.79M Ended 2025-12-31 |
| 1 year earlier | $3.19M Ended 2022-12-31 | $820.1K Ended 2024-12-31 | $5.21M Ended 2024-12-31 | $15.71M Ended 2024-12-31 |
| 2 years earlier | $33.0K Ended 2021-12-31 | $0 Ended 2023-12-31 | $2.23M Ended 2023-12-31 | $16.00M Ended 2023-12-31 |
| 3 years earlier | $158.3K Ended 2020-12-31 | $0 Ended 2022-12-31 | $2.52M Ended 2022-12-31 | $16.20M Ended 2022-12-31 |
| 4 years earlier | $89.8K Ended 2019-12-31 | $0 Ended 2021-12-31 | $3.53M Ended 2021-12-31 | $20.05M Ended 2021-12-31 |